Data to be Presented at the 2025 ESMO Congress

Summary by AI BETAClose X

HUTCHMED announced positive results from its FRUSICA-2 registration trial, evaluating fruquintinib combined with sintilimab for advanced renal cell carcinoma. The study, involving 234 patients, showed a median progression-free survival (PFS) of 22.2 months for the combination therapy, significantly higher than the 6.9 months observed with axitinib/everolimus monotherapy, with a hazard ratio of 0.373 (p<0.0001). The objective response rate (ORR) was also significantly improved at 60.5% compared to 24.3% (Odds Ratio 4.622, p<0.0001), and the median duration of response (DoR) was 23.7 months versus 11.3 months, respectively. Grade 3 or above treatment-emergent adverse events (TEAEs) occurred in 71.4% of patients receiving the combination, versus 58.8% in the monotherapy group. A New Drug Application has been accepted for review in China.

Disclaimer*

UK 100

Latest directors dealings